Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miodrag Zivic

Internal Medicine Beachwood, OH Medical Doctor

NPI 1225011836 CMS profile 146622

25200 Chagrin Blvd Ste 300, Beachwood, OH 44122

Open in the dashboard

General payments

$24,027

1,515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miodrag Zivic of Beachwood, OH is reported in the CMS Open Payments database as having received $24,027 across 1,515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,052 236
2024 General $2,990 166
2023 General $3,139 185
2022 General $3,129 188
2021 General $3,685 231
2020 General $3,241 216
2019 General $3,791 293

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miodrag Zivic
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Miodrag Zivic were reported at $4,052. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Miodrag Zivic Internal Medicine median Middle half National median
2019 $3,791 $159 $48–$570 $163
2020 $3,241 $119 $33–$402 $114
2021 $3,685 $135 $37–$521 $132
2022 $3,129 $141 $42–$496 $149
2023 $3,139 $149 $45–$519 $160
2024 $2,990 $154 $47–$537 $164
2025 $4,052 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,323 129 payments
  2. Pfizer Inc. $2,204 140 payments
  3. AbbVie, Inc. $2,174 130 payments
  4. GlaxoSmithKline, LLC. $1,404 110 payments
  5. Novo Nordisk Inc $1,272 103 payments
  6. Lilly USA, LLC $1,220 93 payments
  7. Amgen Inc. $935 62 payments
  8. Novartis Pharmaceuticals Corporation $935 66 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $747 48 payments
  10. Merck Sharp & Dohme Corporation $621 34 payments
  11. Other $10,192 600 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,978 1,511 payments
  2. Education $49 4 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $1,187 68 payments
  2. FARXIGA $1,171 56 payments
  3. TRELEGY ELLIPTA $1,099 84 payments
  4. Ozempic $953 73 payments
  5. RYBELSUS $795 55 payments
  6. BREZTRI $753 35 payments
  7. LINZESS $747 45 payments
  8. UBRELVY $718 46 payments
  9. TRULICITY $647 50 payments
  10. ENTRESTO $599 48 payments
  11. Other $24,063 1,473 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 256 drugs

Part D claims

36,419

Median for Internal Medicine: 777

Drug cost

$2,333,929

Median for Internal Medicine: $73,373

Branded share of claims

18.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,455 $398,589
Jardiance Empagliflozin Brand 526 $194,766
Ozempic Semaglutide Brand 123 $147,666
Mounjaro Tirzepatide Brand 130 $142,481
Farxiga Dapagliflozin Propanediol Brand 249 $137,993
Ingrezza Valbenazine Tosylate Brand 34 $125,354
Trulicity Dulaglutide Brand 64 $76,235
Januvia Sitagliptin Phosphate Brand 232 $71,420
Xarelto Rivaroxaban Brand 131 $48,418
Linzess Linaclotide Brand 73 $46,411

The 10 drugs with the highest cost, of 256 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$310,164

Of which drugs: $7,345

Medicare patients

783

Average age 77

Services billed

4,852

414 women, 369 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 48%
Diabetes 47%
Heart failure 43%
Depression 40%
Ischemic heart disease 39%
Atrial fibrillation 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 16 16 $1,207
Vaccine for influenza for injection into muscle 90653 Office 11 11 $900
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 13 13 $257

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 52 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$298 54 —
AIRSUPRA
$162 — —
KRYSTEXXA
$161 — —
BREZTRI
$118 — —
TRELEGY ELLIPTA
$108 43 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 52 with Patron

Records

1,515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record